Appointment of new CTO and planned stock exchange listing mark strategic steps toward the company’s next growth phase.
London (UK) July 9th , 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), clinical-stage biopharmaceutical company pioneering novel anti-cancer therapies targeting the tumor microenvironment, announced key leadership and structural initiatives to support its continued growth and evolution.
As part of this progression, Vidac Pharma has appointed Dr. Eyal Breitbart, Ph.D., as Chief Technology Officer (CTO). Dr. Breitbart brings more than two decades of leadership experience across R&D and operations, including senior roles at VBL Therapeutics (NASDAQ: VBLT). His expertise spans the full drug development lifecycle, from early discovery through to Phase 3 clinical trials, along with deep knowledge of complex production processes. His addition enhances Vidac Pharma’s in-house capabilities and operational maturity.
“Dr. Breitbart combines technical depth with real-world execution in drug development, including late-stage work and manufacturing,” said Dr. Max Herzberg, Executive Chairman & CEO of Vidac Pharma. “He’s also a strong collaborator, which fits well with the Vidac culture.”
In parallel, Vidac Pharma is preparing to pursue a listing on a major German stock exchange, and will begin the process of seeking regulatory clearance from BaFin, the German Federal Financial Supervisory Authority. This move is intended to expand the company’s access to international capital markets and support its next phase of development.
These steps reflect Vidac Pharma’s commitment to building a robust foundation for scaling its pipeline of proprietary drug candidates that reverse the Warburg effect—restoring cellular metabolism and reshaping the tumor microenvironment to help overcome treatment resistance.
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.